Venous Thromboembolism News and Research

RSS

Study explores link between hospital procedure volume, surgical outcomes after joint replacements

Patients who undergo elective total hip or total knee arthroplasty at hospitals with lower surgical volume had a higher risk of venous thromboembolism and mortality following the procedure.

7 Jun 2011

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Sanofi US announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%, meeting the study primary endpoint.

4 Jun 2011

Study on entire Swedish population affirms significance of hereditary factors for venous thromboembolism

Venous thromboembolism (VTE) is the third most common type of cardiovascular disease after coronary heart disease and stroke. Researchers at the Centre for Primary Health Care Research in Malmö have mapped the significance of hereditary factors for venous thromboembolism in the entire Swedish population by studying the risk of VTE in children of parents with VTE compared with the children of parents who have not had VTE.

30 May 2011

EMAS publishes position statement on women's post-reproductive health problems in Maturitas journal

Elsevier announced the publication of an important position statement from the European Menopause and Andropause Society in the journal Maturitas on managing menopausal women with a personal or family history of venous thromboembolism.

18 May 2011

Doctors miss blood clots costing millions to the NHS: Report

According to to figures from the NHS Litigation Authority, the NHS has paid out over £112m since 2005 in compensation because doctors have failed to spot or prevent fatal blood clots.

12 May 2011

Pelvic imaging using CT exams are not necessary for VTE diagnosis

A recent study shows that pelvic imaging using computed tomography examinations are not necessary for diagnosing patients with venous thromboembolism and eliminating this exam can significantly reduce a patient's exposure to excessive radiation dose.

3 May 2011

Desirudin more effective for VTE prevention in patients with renal impairment

Desirudin reduced major venous thromboembolism and post-operative bleeding compared with the standard of care, enoxaparin, in patients with poor kidney function undergoing orthopedic surgery, according to a poster presented at the Arteriosclerosis, Thrombosis and Vascular Biology meeting.

3 May 2011

BioInvent, ThromboGenics initiate TB-402 Phase IIb trial for VTE prophylaxis

ThromboGenics NV and co-development partner BioInvent International announce today that the first patient has been dosed in a Phase IIb trial with their novel long-acting anticoagulant TB-402 for the prophylaxis of venous thromboembolism after total hip surgery.

27 Apr 2011

Newer birth control pill raises risk of blood clots

Two human trials in the US and the UK including women from both populations showed that women taking newer forms of oral contraceptives, which include drosperinone, a synthetic version of the hormone progesterone, increased their risk of developing a blood clots by two or three times over those taking older birth control pills that rely on a different form of the hormone known as levonorgestrel.

26 Apr 2011

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.

25 Apr 2011

Bayer's birth control pills may increase risk of venous thromboembolism

The following release is being issued by law firms RodaNast, P.C.; Levin, Fishbein, Sedran & Berman and Feldman & Pinto: According to two new studies published in the online edition of the British Medical Journal, Bayer's birth control pills Yaz and Yasmin, containing a new progestin drospirenone, carry up to triple the risk of serious blood clots over traditional pills containing the progestin levonorgestrel.

25 Apr 2011

Daiichi Sankyo's LIXIANA receives Japanese marketing approval

Daiichi Sankyo Company, Limited, announced today that the company has received its first marketing approval for LIXIANA 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan.

22 Apr 2011

Contraception drospirenone raises risk for blood clots

Two new drug safety studies conducted by researchers at Boston University School of Medicine (BUSM) provide strong evidence that women taking oral contraception with drospirenone have an increased risk of nonfatal venous thromboembolism, or blood clots, compared to women taking oral contraception with levonorgestrel.

21 Apr 2011

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.

6 Apr 2011

Allscripts ED 7.0 receives Complete EHR certification

Allscripts announced today that Allscripts ED™ 7.0, the company's standalone Emergency Department Information System (EDIS), is 2011/2012 compliant and was certified as a Complete EHR on March 2, 2011 by the Certification Commission for Health Information Technology, an ONC-ATCB, in accordance with the applicable hospital certification criteria adopted by the Secretary of Health and Human Services.

30 Mar 2011

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

25 Mar 2011

New scientific statement gives guidance to doctors for treatment of blood clots

Doctors are encouraged to consider therapies in addition to blood thinners to treat certain patients with potentially dangerous blood clots that form in the deep veins and travel to the lungs, according to a new scientific statement from the American Heart Association.

22 Mar 2011

Outcome's TotalQuality Reporting Service to help hospitals meet quality elements of Meaningful Use reporting

Outcome Sciences, Inc., the leading provider of patient registries, studies, and technologies for evaluating real-world outcomes, today announced that its TotalQuality Reporting Service has become a certified electronic health records technology reporting module for the Centers for Medicare and Medicaid's Meaningful Use data submission.

5 Mar 2011

JTH publishes positive TB-402 Phase II trial results for VTE treatment after orthopaedic surgery

ThromboGenics NV and co-development partner BioInvent International announce today that the positive TB-402 Phase II trial results, evaluating the product's efficacy and safety for the prevention of venous thromboembolism afterorthopaedic surgery, have been published in the Journal of Thrombosis and Haemostasis.

14 Feb 2011

Neurologic and neurosurgical patients do not receive therapy to prevent VTE: Study

Patients with strokes, brain tumors and spinal cord injuries are at high risk for life-threatening blood clots, but many do not receive preventive therapy, Loyola University Health System researchers report.